Becton, Dickinson and Company (BD) has purchased a developer of polymer dyes used in flow cytometry, Sirigen Group.

The acquisition will enable BD to expand its life science research reagent platform.

BD Biosciences president Alberto Mas said, "We believe that the acquisition will enable us to develop a continuous cadence of novel, unique dyes and antibody specificity releases over the next two years, significantly expanding our life science research reagent portfolio with high-impact products."

BD executive vice president William Kozy said, "This acquisition is one more example of our pursuit of growth through innovation, in this case investing in a unique technology that enables us to differentiate our life science research reagent portfolio and add value for customers."

BD said the transaction is expected to be dilutive to FY 2012 earnings per share by approximately $0.01.